Medicare seniors get drug discounts—but only if plans pass them on

What it does

This bill requires Medicare Part D drug plans to calculate patient coinsurance (the percentage of drug cost patients pay) based on the actual negotiated price a plan pays for a drug, rather than the higher wholesale acquisition cost list price. Starting in 2026, when a drug's real negotiated price is lower than its list price, seniors will pay coinsurance on the lower amount, reducing their out-of-pocket costs for drugs where plans have negotiated discounts.

Why we flagged it

The bill's sole operative mechanism is a cost-sharing calculation change that reduces senior out-of-pocket expenses for drugs where plans have negotiated discounts. It is a straightforward consumer-protection measure targeting drug affordability.

What the text implies

• Plans may respond by adjusting formulary placement or copayment structures for drugs where actual acquisition cost is significantly lower than WAC, potentially shifting cost-sharing to other tiers or drugs not covered by this rule.
• The rule applies only when actual acquisition cost is lower than wholesale acquisition cost; for drugs where negotiated prices exceed list prices (rare but possible), coinsurance remains based on WAC, creating a one-way ratchet.
• Manufacturer rebates and price concessions are excluded from the coinsurance calculation, meaning the benefit flows to seniors only when plans pass through negotiated savings—plans retaining rebates see no pressure to lower patient cost-sharing.
• The effective date (January 1, 2026) gives plans 11 months to adjust pricing and formulary strategies, potentially allowing them to offset savings through other mechanisms before the rule takes effect.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Seniors pay less out-of-pocket for drugs when plans have negotiated lower prices, because coinsurance is calculated on the actual price paid rather than the inflated list price. The bill directly reduces patient cost-sharing without restricting access or shifting costs to other populations.

Who stands to gain

• Medicare beneficiaries (seniors) — reduced out-of-pocket drug costs

Named in the bill

Medicare Part D, Social Security Act Section 1860D–2, Prescription drug plans (PDPs), Medicare Advantage–Prescription Drug plans (MA–PD), Centers for Medicare & Medicaid Services (CMS), Detailed DIR Report, 42 CFR 423.100

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Feb 12, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 12, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $6,292,990 in lobbying spend. A filing names 37 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Donald Davis, the sponsor, reported $1,617,446 in PAC receipts in the 2026 cycle.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• Chronic Care Policy Alliance — $0 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.